Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04863222 · ClinicalTrials.gov registry record · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
A Phase 4 study of Indirect Pulp Cap and Pulpotomy, sponsored by Geisinger Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 646
- Enrollment target
- 1
- Study location
NCT04863222 is a Phase 4 study of Indirect Pulp Cap and Pulpotomy that is actively recruiting participants, run by Geisinger Clinic. The registered enrollment target is 646 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04863222, a Phase 4 study of Indirect Pulp Cap and Pulpotomy, is actively recruiting participants, sponsored by Geisinger Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 646 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.
Conditions Studied
Interventions
- DEVICE Biodentine
- BIOLOGICAL mineral trioxide aggregate (MTA)
Study Locations (1)
Pennsylvania
- Geisinger - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04863222
The ClinicalTrials.gov registry entry for NCT04863222 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Indirect Pulp Cap appearing as the primary indexed condition, and to 2 interventions - of which Biodentine is the first listed.
NCT04863222 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04863222 about?
NCT04863222 is a clinical study titled "Clinical and Radiographic Success of MTA vs Biodentine". The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Bi...
What is the current status of trial NCT04863222?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 646 participants. The study started on 2021-11-12. Estimated completion is 2026-12-01.
What conditions does trial NCT04863222 study?
This clinical trial studies the following conditions: Indirect Pulp Cap, Pulpotomy.
What interventions are being tested in trial NCT04863222?
The interventions under investigation include: Biodentine (DEVICE), mineral trioxide aggregate (MTA) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04863222?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04863222 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Indirect Pulp Cap
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.